1

Transcatheter Cardiovascular Therapeutics

Investor UpdateOctober 30, 2017

Kevin Ballinger

Executive Vice President and President, Interventional Cardiology

Professor Ian Meredith, A.M.

Executive Vice President and Global Chief Medical Officer

Nicholas Spadea-Anello

Structural Heart-LAAC Vice President and General Manager

22

Safe Harbor for Forward-Looking Statements and Regulatory Disclaimers

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act

of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be

identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar

words. These forward-looking statements are based on our beliefs, assumptions and estimates using

information available to us at the time and are not intended to be guarantees of future events or

performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties

materialize, actual results could differ materially from the expectations and projections expressed or implied

by our forward-looking statements.

Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or

to be filed with the Securities and Exchange Commission under the headings “Risk Factors” and “Safe Harbor

for Forward-Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our

forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-

looking statements to reflect any change in our expectations or in events, conditions, or circumstances on

which they may be based, or that may affect the likelihood that actual results will differ from those contained

in the forward-looking statements.

Market Estimates:

Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are

BSX internal estimates.

Regulatory Disclaimers:

LOTUS EdgeTM and ACURATE neoTM Valves may only be used in countries where they are approved for use.

LOTUS Edge Valve and iSLEEVETM are not available for sale in the European Economic Area. For education

purposes only.

LOTUS EdgeTM Valve and iSLEEVETM are investigational devices in the United States and are not available for

sale.

WATCHMAN FLXTM is pending CE Mark. Not available for use or sale in the United States.

33

Broadest Portfolio to Drive IC Category Leadership

Structural HeartCoronary Therapies

StentsComplex

PCI

PCI

GuidanceTAVR LAAC Mitral

Coronary Therapies Structural Heart Total Cardiology

2016 Market Size $7.5B $3B $10.5B

5yr CAGR (2016-2021) 1% +17% +7%

Est. 2021 Market Size $8.0B $6.5B $14.5B

Est. 2021 Share Position #1 #2 #1

44

Diversifying into Faster Growth IC Markets

54%36%

10%

~30%

2016

Structural Heart

Complex PCI

Stents

2021E

Maintain coronary therapies leadership + grow structural heart platforms

= healthy IC portfolio diversification

BSX IC Revenue Mix

Market Size = $10.5B Market Size = $14.5B

~40%

~30%

5 E = expected *Pending

Compelling TAVR Portfolio

5

ACURATE neo™ Aortic Valve System – EU

• Commercial expansion with ACURATE neo TF and TA

• Launch next generation ACURATE neo AS H2:18E

LOTUS Edge™ Aortic Valve System

• EU launch Q1:18E and U.S. launch mid-2018E

Accessory Devices

• Market leading Safari2™ Guidewire

• iSLEEVE™ Expandable Sheath

Clinical Programs

• LOTUS Edge REPRISE IV Intermediate Risk U.S. study

• Enrollment mid-2018E

• ACURATE neo U.S. IDE*

• Enrollment H2:18E

Expand Your Reach

More Options for Better Outcomes

6

WATCHMAN™ LAAC Device Global Leadership

Commercial Activities

• Therapy development efforts continue

• Focus on penetrating U.S. indicated population

• 1% of penetration = $250M

• TV campaign showing strong patient activation

• Pilot market growth is above national average

• Main CMS DRG for LAAC increased ~11% on Oct 1

• Received CE Mark for an updated WATCHMAN DFU

• Allows for DAPT + shorter OAT duration post implant

Clinical Milestones

• Completed Japan Salute IDE clinical trial in Q3

• PREVAIL 5-year outcomes highlighted as LBCT Thursday

Product Pipeline

• WATCHMAN FLX™

• PINNACLE FLX U.S. IDE – enrollment mid-2018E

• FLXibility EU Post-Market Study – enrollment mid 2018E

WATCHMAN™

WATCHMAN FLX™

E = expected

77

Unrivaled DES Innovation

• YTD 2017: DES growth at market rates despite

double digit 2016 growth comparison

• Comprehensive clinical science:

• SYNERGY™ studied in ~20,000 patients

• Unique and differentiated tiered portfolio

• Future product innovation:

• 48 mm SYNERGY™

• 4.5 / 5.0mm SYNERGY™

• Short DAPT indication

• Trans-radial enhanced NG DES system

#1US DES

Market Share

Strong DES Portfolio and U.S. Market Leader for 14 quarters

8

Unmatched Complex PCI and Imaging Portfolios

Robust and consistent product cadence continues in 2018

Clear Leadership in $2.5B

Complex PCI MarketContinued Investment in

Imaging Portfolio

New Devices for cPCI

9

IC Category Leadership via Breadth of Portfolio